Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Clinical Trial

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Benzinga

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions.

Benzinga

Jim Cramer Expects Palantir To Reach New All-Time High

Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gum disease treatment slows the thickening of arteries, clinical trial shows

New trial results show that intense gum disease treatment reduces how much the carotid artery narrows in otherwise healthy individuals. This suggests oral health should be taken seriously as a contributing factor in cardiovascular disease.

LiveScience

BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know

BioXcel Therapeutics Inc. (NASDAQ:BTAI) experienced significant after-hours momentum, jumping 19.09% to $6.24 in the after-hours trading session on Tuesday, as investors got ready for the release of important clinical trial results.

Benzinga

Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress

Shares of Protagenic Therapeutics Inc (NASDAQ:PTIX) are trading sharply higher Thursday afternoon, soaring over 100% midday after the company announced a key clinical milestone.

Benzinga

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Inside the World of Modern Clinical Trials: How Innovation Is Transforming Drug Development

Clinical trials have long served as the critical link between scientific discovery and real-world medical treatments. But in recent years, the way these trials are designed, managed, and executed has undergone a major transformation

inkl

French scientists say light stimulation shows promise in slowing Parkinson's disease

An early-stage clinical trial in France appeared to help restore some brain function for three Parkinson's patients.

Euronews

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

On Wednesday, Incannex Healthcare Inc. (NASDAQ:IXHL) released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide.

Benzinga

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.

Benzinga

3 Bullish Biotech Stocks With Explosive Growth Trends

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

MarketBeat

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ:SRPT) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company’s experimental treatments.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Plan to link rare cancer sufferers to suitable clinical trials clears Commons

Allison Gardner MP dedicated her support for the Rare Cancers Bill to her mother, who died of pancreatic cancer.

LiveScience

Metformin may prevent severe morning sickness

Taking the diabetes drug metformin before pregnancy may reduce the risk of debilitating morning sickness by 70%, early data hint. But a clinical trial is still needed to confirm this finding.

Benzinga

ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results

ProKidney Ord Shs Class A (NASDAQ:PROK) shares are trading sharply higher Wednesday morning, following a marked surge on Tuesday driven by positive clinical trial data for its chronic kidney disease (CKD) treatment.

Benzinga

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis.

Get all your
news in one place.

100's of premium titles.
One news app.

LiveScience

Ozempic-style drugs treat type 1 diabetes, not only type 2, study finds

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes.

The Conversation

People with severe diabetes cured in small stem cell trial

The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a new clinical trial were cured of their diabetes one year after receiving an advanced stem cell therapy.

Benzinga

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

Shares of Nektar Therapeutics (NASDAQ:NKTR) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin on June 24, 2025.

Tom’s Hardware

China launches first-ever invasive brain-computer interface clinical trial — Tetraplegic patient could skillfully operate racing games after just three weeks

China's first in-human clinical trials of an invasive brain-computer interface (BCI) have launched.

The Guardian - UK

Ministers plan to use NHS app to expand clinical trials as part of UK-wide drive

Patients in England will be matched with studies and encouraged to take part via smartphone notifications

The Independent UK

This experimental drug could help young people with a rare and aggressive form of ALS

Researchers say a full-scale clinical trial of the therapy could help many patients with a particularly aggressive form of ALS

LiveScience

2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayed

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University College London

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.